Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Henk M.W. Verheul, Tanja D. de Gruijl, Marco B. Polee, Paul Hamberg, Charlotte M. Huijts, Maartje Los, Inge M. Werter, Sinéad. M. Lougheed, Hans van Vliet, John B. A. G. Haanen, Helgi H. Helgason, Metin Tascilar
Publikováno v:
Werter, I M, Huijts, C M, Lougheed, S M, Hamberg, P, Polee, M B, Tascilar, M, Los, M, Haanen, J B A G, Helgason, H H, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ', Cancer Immunology, Immunotherapy, vol. 68, no. 5, pp. 787-798 . https://doi.org/10.1007/s00262-019-02313-z
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798
Contains fulltext : 207393.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of rapamycin (mTOR) inh
Autor:
Willemijn van den Ancker, Hetty J. Bontkes, Tanja D. de Gruijl, Jurjen M. Ruben, Erik Hooijberg, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Theresia M. Westers
Publikováno v:
Ruben, J M, van den Ancker, W, Bontkes, H J, Westers, T M, Hooijberg, E, Ossenkoppele, G J, de Gruijl, T D & van de Loosdrecht, A A 2014, ' Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines ', Cancer Immunology and Immunotherapy, vol. 63, no. 4, pp. 335-345 . https://doi.org/10.1007/s00262-013-1515-6
Cancer Immunology and Immunotherapy, 63(4), 335-345. Springer Science and Business Media Deutschland GmbH
Cancer Immunology and Immunotherapy, 63(4), 335-345. Springer Science and Business Media Deutschland GmbH
Since few leukemia-associated antigens (LAA) are characterized for acute myeloid leukemia (AML), apoptotic tumor cells constitute an attractive LAA source for DC-based vaccines, as they contain both characterized and unknown LAA. However, loading DC